Vontobel Holding Ltd. Lowers Stock Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Vontobel Holding Ltd. lowered its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 62.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 46,121 shares of the medical equipment provider’s stock after selling 77,535 shares during the quarter. Vontobel Holding Ltd.’s holdings in Intuitive Surgical were worth $22,658,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Capital Research Global Investors acquired a new position in shares of Intuitive Surgical in the 1st quarter valued at about $374,390,000. Vanguard Group Inc. lifted its position in Intuitive Surgical by 1.6% during the first quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock valued at $12,319,358,000 after buying an additional 493,126 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its stake in Intuitive Surgical by 51.2% during the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 893,341 shares of the medical equipment provider’s stock worth $356,524,000 after buying an additional 302,382 shares during the period. Strategic Financial Concepts LLC increased its position in shares of Intuitive Surgical by 40,221.4% in the second quarter. Strategic Financial Concepts LLC now owns 266,121 shares of the medical equipment provider’s stock worth $1,184,000 after acquiring an additional 265,461 shares in the last quarter. Finally, GQG Partners LLC purchased a new position in shares of Intuitive Surgical in the 1st quarter valued at $99,523,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Ratings Changes

ISRG has been the subject of several recent research reports. Stifel Nicolaus increased their price target on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a report on Friday, July 19th. Piper Sandler lifted their price objective on shares of Intuitive Surgical from $490.00 to $495.00 and gave the company an “overweight” rating in a research note on Friday, July 19th. Citigroup upped their target price on shares of Intuitive Surgical from $512.00 to $560.00 and gave the company a “buy” rating in a research note on Thursday, August 22nd. BTIG Research lifted their price target on shares of Intuitive Surgical from $494.00 to $518.00 and gave the stock a “buy” rating in a research note on Monday. Finally, Raymond James upped their price objective on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research report on Monday. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $474.16.

Intuitive Surgical Trading Down 0.4 %

ISRG stock opened at $476.59 on Thursday. The firm has a market cap of $169.05 billion, a P/E ratio of 86.03, a P/E/G ratio of 5.40 and a beta of 1.39. The stock’s 50 day simple moving average is $482.49 and its 200 day simple moving average is $436.65. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last posted its quarterly earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. Intuitive Surgical had a net margin of 27.65% and a return on equity of 13.04%. The company had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period last year, the firm posted $1.18 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. On average, research analysts forecast that Intuitive Surgical, Inc. will post 5.22 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Robert Desantis sold 1,413 shares of the firm’s stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now owns 5,506 shares of the company’s stock, valued at approximately $2,414,931.60. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the stock in a transaction on Friday, July 26th. The stock was sold at an average price of $438.60, for a total value of $619,741.80. Following the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,414,931.60. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Amy L. Ladd sold 450 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $490.28, for a total transaction of $220,626.00. Following the transaction, the director now directly owns 821 shares of the company’s stock, valued at approximately $402,519.88. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 53,120 shares of company stock valued at $25,528,753 over the last quarter. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.